Hepatitis C virus (HCV) has chronically infected million peoples worldwide. Spontaneous viral clearance occurs in 25% of affected patients. The standard regimen to treat HCV infection is the combination of pegylated interferon and ribavirin.
and lower than East Asian populations (more than 90%). Any population has a relatively unique pattern of genes polymorphism, which has significant role in disease susceptibility, immunogenetics and pharmacogenetics. As the C allele is the favorable allele for predicting SVR in patients with HCV, its application is important in personalized treatment plan to maximize the drug response and minimize the toxicity. 
